The positive PK data de-risks SKNY-1's oral formulation and supports advancement toward IND-enabling studies. Traders should watch for next preclinical efficacy updates and any partnership or financing announcements, as MIRA has a $40M market cap and likely needs capital to fund clinical development.
Price Chart
Executive Summary
MIRA Pharmaceuticals reported positive preclinical pharmacokinetic results for its oral obesity and addiction drug candidate SKNY-1, demonstrating favorable oral bioavailability, robust brain penetration, and substantial liver exposure with once-daily dosing potential. The data supports the drug's differentiated profile but remains preclinical, with no human efficacy or safety data yet established.
Key Facts
- SKNY-1 demonstrated favorable oral bioavailability and reproducible systemic exposure in preclinical studies.
- Robust brain penetration and substantial liver exposure were observed following oral administration.
- Peak plasma concentrations occurred 6-12 hours post-dose, supporting potential once-daily oral dosing.
- SKNY-1 showed no anxiety-related behavioral effects in a validated preclinical cannabinoid model, distinguishing it from earlier CB1-targeting therapies like rimonabant.
- The drug candidate combines biased CB1 receptor modulation, partial CB2 agonism, and selective MAO-B inhibition.
Financial Impact
No financial data reported; preclinical milestone with no revenue or earnings impact.
Risk Factors
- Preclinical results may not translate to human clinical trials.
- SKNY-1 has not been approved by the FDA and its safety/efficacy in humans is unproven.
- Highly competitive obesity drug market with established GLP-1 therapies.
- Company may require additional financing to advance SKNY-1 into clinical development.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-032091 |
| Exhibit: ex99-1.htm | 0001493152-26-032091 |
| Document: 0001493152-26-032091-index-headers.html | 0001493152-26-032091 |
| Document: 0001493152-26-032091-index.html | 0001493152-26-032091 |
| Document: 0001493152-26-032091.txt | 0001493152-26-032091 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 5d ago | 8-K | $0.6290 $0.6195 | ▼ −1.51% | ▼ −0.99% | $0.5330 (−15.26%) |
Oct 22, 2026 5d ago | Press Release | $0.6289 $0.6195 | ▼ −1.49% | ▼ −0.97% | $0.5330 (−15.25%) |
Sep 17, 2026 5w ago | 8-K | $0.7593 $0.8323 | ▲ +9.61% | ▲ +9.73% | $0.5330 (−29.80%) |
Sep 17, 2026 5w ago | Press Release | $0.7593 $0.8323 | ▲ +9.61% | ▲ +9.73% | $0.5330 (−29.80%) |
Sep 1, 2026 8w ago | 8-K | $0.8600 $0.8495 | ▼ −1.22% | ▼ −1.66% | $0.5330 (−38.02%) |
Aug 6, 2026 11w ago | 8-K | $0.6782 $0.7400 | ▲ +9.11% | ▲ +8.50% | $0.5330 (−21.41%) |
Jul 10, 2026 15w ago | 8-K | $0.9245 $0.9097 | ▼ −1.60% | ▼ −0.84% | $0.5330 (−42.35%) |
Jul 6, 2026 16w ago | 8-K | $0.9549 $0.9478 | ▼ −0.74% | ▼ −0.27% | $0.5330 (−44.18%) |
Jun 17, 2026 18w ago | 8-K | $0.9782 $0.9524 | ▼ −2.64% | ▼ −3.42% | $0.5330 (−45.51%) |
Jun 8, 2026 20w ago | 8-K | $0.9767 $0.9802 | ▲ +0.36% | ▲ +1.93% | $0.5330 (−45.43%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers